cholest-5-en-3β, 7α-diol | 907574-88-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: cholest-5-en-3β, 7α-diol
• 英文别名: cholest-5-ene-3β,7α-diol；5-cholesten-3β,7α-diol；7β-hydroxycholesterol；7 β-hydroxy cholesterol；7 α-hydroxycholesterol；7β-hydroxylcholesterol；7 beta- hydroxycholesterol；7-alpha-hydroxycholesterol；7a-hydroxy cholesterol；7b-hydroxy cholesterol；7-hydroxycholesterol；7 beta-Hydroxy Cholesterol；(7R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
• CAS: 907574-88-3
• 化学式: C₂₇H₄₆O₂
• 分子量: 402.661
• InChiKey: OYXZMSRRJOYLLO-ISPKDCJXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cholest-5-en-3β, 7α-diol 在 T406石油添加剂 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以95%的产率得到7-oxocholesterol
  参考文献：
  名称：

  Parish, Edward J.; Chitrakorn, Sarawanee, Synthetic Communications, 1985, vol. 15, # 5, p. 393 - 400

  摘要：

  DOI：

文献信息

• Apoptogenic and antiproliferative analogs of ceramide
  申请人：Deigner, Hans-Peter

  公开号：EP1580187A1

  公开（公告）日：2005-09-28

  Described are analogs of ceramide which have apoptogenic and antiproliferative properties as well as pharmaceutical compositions containing these analogs. Also described is the therapeutic use of the ceramide analogs, e.g. for inhibiting proliferation, preferably in cancer therapy, or increased angiogenesis or for modulating apoptosis.

  描述了具有凋亡和抗增殖特性的神经酰胺类似物，以及含有这些类似物的药物组合物。还描述了神经酰胺类似物的治疗用途，例如用于抑制增殖，特别是在癌症治疗中，或增加血管生成或调节凋亡。
• NANOMATERIALS
  申请人：Guide Therapeutics, Inc.

  公开号：US20210169804A1

  公开（公告）日：2021-06-10

  Lipid nanoparticle compositions for delivery of nucleic acids are described. The lipid nanoparticle may contain a conformationally constrained ionizable lipid as part of the composition. These compositions may allow for delivery of cargo without the need for a targeting ligand.

  描述了用于传递核酸的脂质纳米粒子组合物。脂质纳米粒子可能包含作为组合物的一部分的构象受限的可离子化脂质。这些组合物可能允许传递货物而无需靶向配体。
• [EN] OXYSTEROLS AND METHODS OF USE THEREOF<br/>[FR] OXYSTÉROLS ET LEURS MÉTHODES D'UTILISATION
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2017173358A1

  公开（公告）日：2017-10-05

  Compounds are provided according to Formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein A, R1, and R5 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

  根据公式（I）提供化合物及其药用可接受的盐和药物组成；其中A、R1和R5如本文所定义。本发明的化合物被认为对预防和治疗各种疾病条件有用。
• [EN] OXYSTEROLS AND METHODS OF USE THEREOF<br/>[FR] OXYSTÉROLS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2017007832A1

  公开（公告）日：2017-01-12

  Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, and R8 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

  根据公式（I）提供化合物及其药用盐，以及药物组合物；其中R1、R2、R3、R4、R5和R8如本文所定义。本发明的化合物被认为对预防和治疗各种疾病条件有用。
• [EN] CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF<br/>[FR] COMPOSÉS LIPIDIQUES CLIVABLES, COMPOSITIONS LES CONTENANT ET UTILISATIONS ASSOCIÉES
  申请人：SANOFI PASTEUR

  公开号：WO2022013439A1

  公开（公告）日：2022-01-20

  The disclosure relates to novel lipidic compounds, method of manufacturing lipid nanoparticles (LNPs) containing thereof, lipid nanoparticles (LNPs) containing thereof, and the use of the LNPs for the delivery of nucleic acid. The lipidic compounds as disclosed herein is a cleavable lipidic compound comprising at least one terminal radical of formula (I): Y-(CHR)n-Z-(CHR')p-Q * (I) wherein: - * is the end linked, directly or not, to one C10 to C55 lipophilic or hydrophobic tail-group; - Y is a radical selected in the group consisting of methyl, methoxy, trifluoromethyl, imidazolyl, or is one hydrogen; - Z is a radical -NH-CH2-CO-O-** or a radical -CR''(NH2)-CO-O-** with ** that is the end closest to Q and R'' that is selected in the group consisting of hydrogen, methyl radical and trifluoromethyl radical; - Q is a radical -NH-CH2-CO-O-*** or a radical -CR''(NH2)-CO-O-*** with R'' selected in the group consisting of hydrogen, methyl radical and trifluoromethyl radical and *** that is the end linked, directly or not, to said lipophilic or hydrophobic tail-group; - R et R' are, independently one from the other, one hydrogen, one methyl radical or one trifluoromethyl radical; - n et p are independently one from the other 0, 1 or 2; or one of its pharmaceutically acceptable salts and with said compound being in all the possible racemic, enantiomeric and diastereoisomeric isomer forms.

  该披露涉及新型脂质化合物，制造含有脂质纳米颗粒（LNPs）的方法，含有脂质纳米颗粒（LNPs），以及将LNPs用于传递核酸。所述的脂质化合物是一种可切割的脂质化合物，包括至少一个式（I）的末端基团：Y-(CHR)n-Z-(CHR')p-Q *（I）其中：- *是末端连接的，直接或间接连接到一个C10至C55的亲脂性或疏水性尾基团；- Y是在甲基，甲氧基，三氟甲基，咪唑基中选择的基团，或是一个氢原子；- Z是一个基团-NH-CH2-CO-O-**或一个基团-CR''(NH2)-CO-O-**，其中**是最接近Q的末端，R''在氢原子，甲基基团和三氟甲基基团中选择；- Q是一个基团-NH-CH2-CO-O-***或一个基团-CR''(NH2)-CO-O-***，其中R''在氢原子，甲基基团和三氟甲基基团中选择，***是直接或间接连接到所述亲脂性或疏水性尾基团的末端；- R和R'是彼此独立的氢原子，甲基基团或三氟甲基基团；- n和p是彼此独立的0、1或2；或其药用可接受的盐，所述化合物以所有可能的外消旋、对映异构体和顄对映异构体形式存在。